Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.
Corcept Therapeutics (CORT) merits a Hold rating for moderate-risk investors with a medium-term horizon. The company has a strong commercial base, a large cash position, positive clinical evidence and a newly approved oncology product. However, the valuation remains demanding while recent profitability has weakened.
The core growth case rests on two named developments. First, Corcept raised 2026 revenue guidance to $950M-$1.05B after reporting Q1 revenue of $164.9M, up 4.9% from $157.2M. Second, Lifyorli, the relacorilant and nab-paclitaxel combination, received FDA approval for platinum-resistant ovarian cancer and gained preferred-regimen status in NCCN guidelines.
The longer-term opportunity is substantial. Management expects the Cushing's syndrome business to reach at least $2B in annual revenue by the end of the decade and expects Lifyorli to exceed $1B in U.S. annual revenue over the same period. Those forecasts are supported by record new prescriptions, record prescriber counts and positive ROSELLA survival data, but they remain management targets rather than realized revenue.
The counterweight is valuation and execution. CORT trades at 261.6x trailing earnings and 112.4x forward earnings, while Q1 2026 produced a $0.30 diluted loss per share and a $49.6M operating loss. The stock's growth assets are valuable, but the price already assumes a meaningful recovery in earnings and successful expansion beyond Korlym.
Corcept Therapeutics is a Redwood City, California-based biopharmaceutical company founded in 1998 and listed on the Nasdaq. It had 730 employees and focuses on medicines that modulate cortisol activity in endocrinology, oncology, metabolic disease and neurology.
Corcept's strategy is to use its cortisol biology across several indications rather than rely on a single disease application. Relacorilant is being developed for Cushing's syndrome and cancer, miricorilant is in MASH, dazucorilant is being advanced in ALS, and nenocorilant is being evaluated with immunotherapy.
The company generated $761.4M of revenue in 2025, compared with $675.0M in 2024 and $482.4M in 2023. That record establishes a meaningful commercial foundation, although the 2025 income statement shows that research, development and launch spending consumed much of the operating leverage.
Corcept organizes its business around therapeutic areas rather than a set of separately reported financial segments. Endocrinology remains the economic center of gravity. Management said the endocrine business represented the bulk of the 2026 revenue guidance range, giving Korlym and the broader hypercortisolism franchise the largest near-term influence on results.
The endocrinology franchise is expanding through better disease identification. CATALYST found hypercortisolism in 23.8% of 1,057 patients with difficult-to-control diabetes, while management reported that MOMENTUM found hypercortisolism in 27% of patients with resistant hypertension. These findings expand the pool of patients who can be evaluated for cortisol-driven disease.
Oncology became a commercial business in 2026 with the approval and launch of Lifyorli for platinum-resistant ovarian cancer. The product has a separate growth profile from Korlym because it is used alongside chemotherapy and targets a broader oncology treatment pathway.
Metabolic and neurologic programs provide additional option value. The 175-patient MONARCH Phase 2b study of miricorilant in MASH is fully enrolled, while DAZALS produced an exploratory 84% reduction in one-year mortality risk at the 300-milligram dose. DAZALS did not meet its primary functional-decline endpoint, so the ALS opportunity carries a higher clinical risk than the commercial endocrinology franchise.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Korlym remains the flagship commercial product. Its active ingredient, mifepristone, blocks cortisol at the glucocorticoid receptor and treats the effects of excessive cortisol without directly destroying the body's ability to produce the hormone.
CATALYST provides a concrete clinical foundation for wider use. Patients treated with Korlym experienced a 1.47% reduction in HbA1c over 24 weeks compared with a 0.15% reduction for placebo, along with greater reductions in body weight and waist circumference.
Korlym has two commercial weaknesses. Mifepristone also binds to the progesterone receptor, creating risks such as endometrial thickening and vaginal bleeding, and generic Korlym from Teva has competed in the United States since January 2024. The authorized generic also lowered average price in 2025, even as sales volume rose.
Lifyorli is the strategic upgrade to the product portfolio. In ROSELLA, relacorilant plus nab-paclitaxel reduced the risk of death by 35% versus nab-paclitaxel alone, with a hazard ratio of 0.65 and a median overall survival of 16.0 months versus 11.9 months.
Corcept's main innovation is its selective cortisol-modulator platform. The company has discovered more than 1,000 proprietary compounds that bind to the glucocorticoid receptor without affinity for the progesterone, estrogen or androgen receptors.
Relacorilant is the clearest example of that advantage. The 10-K states that relacorilant does not meaningfully increase cortisol, does not cause hypokalemia and does not prolong the QT interval. In Korlym's pivotal trial, 44% of patients experienced hypokalemia, giving relacorilant a potentially meaningful tolerability distinction.
The platform also creates cross-indication leverage. ROSELLA supports the use of glucocorticoid receptor antagonism in ovarian cancer, while ongoing studies test the same biology in endometrial, cervical, pancreatic and prostate cancers. Patents covering the company's compounds and uses have expiration dates ranging from 2028 to 2042.
The principal innovation risk is that biology does not guarantee regulatory or commercial success. The FDA issued a Complete Response Letter for relacorilant in Cushing's syndrome on December 30, 2025, stating that additional efficacy evidence was required. Corcept resubmitted the application on May 27, 2026, making regulatory execution part of the investment case.
Corcept relies on contract manufacturers for mifepristone, finished tablets and product candidates. The company has purchased and holds significant quantities of active pharmaceutical ingredient, which provides a buffer against some supply interruptions but does not remove contract-manufacturing risk.
The specialty-pharmacy transition was a major operating event. Corcept shifted substantially all specialty-pharmacy services from Optime to Curant in the fourth quarter of 2025, and management reported an insurance prior-authorization backlog during the transition.
Lifyorli's launch infrastructure was stronger than the timing of its approval might suggest. Corcept said sales, marketing, medical and market-access teams were trained by approval, product was available within five days, and a patient-support hub had been launched. Management also plans to add specialty-pharmacy support in the fourth quarter of 2026 as prescription volume grows.
The relevant market is not the entire pharmaceutical industry but a set of specialty indications with high medical need. Corcept's 10-K cites approximately 20,000 prevalent U.S. Cushing's syndrome patients and about 3,000 new patients annually, while CATALYST and MOMENTUM point to additional cases among patients with difficult-to-control diabetes and resistant hypertension.
Management estimates that the current Cushing's syndrome business can reach at least $2B in annual revenue by the end of the decade. That target depends on greater screening, diagnosis and treatment rather than only price increases, a favorable feature for long-term market expansion.
The broader global pharmaceutical market is estimated at $1.89T in 2026 and $2.62T by 2031, representing a 6.7% compound annual growth rate. Corcept's 2026 revenue guidance of $950M-$1.05B implies a much faster growth profile than the general pharmaceutical market if achieved.
Lifyorli adds a second market with larger commercial breadth than classic Cushing's syndrome. Corcept expects the product to exceed $1B in U.S. annual revenue by the end of the decade, supported by its all-comer indication, oral administration and NCCN preferred-regimen status.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Corcept serves several customer groups at once. Endocrinologists and other physicians diagnose and prescribe treatment, payers determine coverage and authorization, specialty pharmacies handle fulfillment, and patients depend on support programs to maintain access.
The company is targeting approximately 5,000 U.S. physicians who account for nearly 90% of platinum-resistant ovarian cancer treatment volume. More than 200 physicians had written Lifyorli prescriptions within the first 36 days of launch, with adoption spanning community oncology, gynecology and academic settings.
The endocrine customer base is expanding through physician education. CATALYST was published in Diabetes Care and referenced in the March 2026 AACE diabetes guidance document, while MOMENTUM results were presented at the American College of Cardiology meeting. Those dated events can increase screening among physicians treating resistant metabolic disease.
Payer friction remains part of the customer experience. Management said annual insurance reauthorization procedures can interrupt coverage for one or two months, forcing Corcept to provide free drug bridges while reimbursement is restored.
In Cushing's syndrome, Corcept competes with surgery, radiation and medicines that use different mechanisms. Named competitors include Recordati's Signifor and Isturisa, Xeris Biopharma's Recorlev, off-label ketoconazole and metyrapone, and Teva's generic Korlym.
Generic Korlym is the most direct threat because it targets the same active ingredient. Corcept's 2025 average price declined 17.7% as authorized-generic volume increased, although a price increase in August 2025 partly offset that decline.
Lifyorli enters a more favorable competitive position in platinum-resistant ovarian cancer. The company stated that Lifyorli is approved for all patients, while KEYTRUDA is approved for a PD-L1 population that represents approximately 35% to 40% of patients after testing rates are considered.
The competitive advantage in oncology is therefore evidence-based but still early. ROSELLA's 0.65 overall-survival hazard ratio and NCCN preferred status create a strong opening, while actual market share and long-term prescribing behavior remain tied to launch execution.
The pharmaceutical backdrop is supportive for specialty innovation. FDA data show that 23 of 46 novel drugs approved in 2025 received orphan-drug designation, and 33 of 46 used at least one expedited regulatory program. Corcept's Cushing's syndrome and ALS programs have orphan designations, while dazucorilant also has Fast Track designation.
The same regulatory environment carries cost pressure. FDA materials identify generic and biosimilar competition as tools for lowering drug costs, and Corcept already faces generic Korlym from Teva. The company therefore benefits from orphan-disease economics while operating in a market that rewards lower-cost alternatives.
Supply-chain resilience is also a macro issue for specialty pharmaceuticals. Corcept's reliance on contract manufacturers and its decision to hold significant quantities of active pharmaceutical ingredient show that manufacturing continuity is important to product availability, especially as the company adds Lifyorli and expands its specialty-pharmacy network.
The geographic growth figures are less important to CORT than U.S. execution because Korlym and Lifyorli are commercialized primarily in the United States. North America accounted for 41.2% of the global pharmaceutical market in 2025, while Corcept's disclosed revenue targets are specifically tied to the U.S. market.
A large cash position and an A balance sheet grade give Corcept room to fund launches and pipeline work without immediate financing pressure.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose 4.9% to $164.9M, but a $0.30 diluted loss per share and a $49.6M operating loss show profitability has weakened.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $950M-$1.05B, with the endocrine franchise still expected to supply most of the top-line base.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →CORT trades at 261.6x trailing earnings and 112.4x forward earnings, leaving little margin for execution missteps.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report's fair value sits at $92, with upside tied to Korlym growth, Lifyorli adoption, and a return to stronger earnings.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Corcept Therapeutics has moved beyond a one-product rare-disease story. Korlym generated a substantial commercial base, CATALYST and MOMENTUM expanded the diagnosed-patient opportunity, and Lifyorli added a second commercial product after strong ROSELLA survival data.
The investment case is strongest when viewed as a combination of durable biology and improving commercial reach. The company owns more than 1,000 selective cortisol-modulator compounds, carries low debt and has a pipeline spanning Cushing's syndrome, ovarian cancer, MASH and ALS.
The stock, however, demands proof. Q1 2026 revenue grew only 4.9% year over year while the company posted a $31.2M net loss, and the share price was already close to the $92.00 valuation anchor. For a moderate-risk investor, the disciplined position is Hold until revenue growth, Lifyorli adoption and earnings conversion better match the premium embedded in CORT.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Corcept Therapeutics Incorporated (CORT) jumps after hours as investors react to its Q2 2026 earnings event and a fresh price-target hike from Canaccord Genuity. The stock moved sharply above its prior 52-week high, but valuation remains stretched and analyst views are sharply divided.
Tapestry, Inc. (TPR) topped EPS and revenue estimates, yet the stock slumps sharply as investors dig into what really matters: Coach’s growth engine, Kate Spade’s slower rebound, margin expansion and whether the company can sustain its ahead-of-plan execution beyond a modest quarterly beat.
Alliance Laundry Holdings Inc. (ALH) beat EPS and held revenue in line, but the stock slips as investors focused on muted top-line growth and the market’s higher bar. This deep-dive unpacks margin expansion, segment trends, leverage reduction, and why stronger guidance still wasn’t enough.